Non-Opioid Depressants: Benzos, Z-Drugs, and the Ones You Didn't Know About
Prescribed to calm anxiety and sleep. Capable of producing some of the hardest withdrawals in medicine.
Body — 8 lenses: [Science: GABA-A positive allosteric modulators (benzos, Z-drugs), GHB at GHB receptor + GABA-B. Biology: sedation, anterograde amnesia, paradoxical disinhibition. Withdrawal: kindling effect, protracted symptoms, seizure risk. Psychology: chronic benzo dependence via therapeutic use; iatrogenic pathway; cognitive effects. Policy: Schedule IV (benzos, Z-drugs), II (barbiturates), I (GHB), but designer benzos (etizolam, flubromazolam) circulate as novel psychoactives. Trends: benzo Rx rising; designer benzo detection in overdose deaths; fentanyl-benzo co-use lethal combination. Social: the “mother’s little helper” legacy; TikTok-era anxiety prescribing. Treatment: slow taper (Ashton Manual), CBT for anxiety, flumazenil only for overdose. Harm reduction: NEVER mix with opioids/alcohol, test-strip availability for designer benzos, naloxone doesn’t reverse benzo respiratory depression.]
Sources Cited
- 01.A
- 02.Bhttps://www.benzoinfo.comBenzodiazepine Information Coalition
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionPeer-Reviewed Research
Continue reading
More from this section
The Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction
Psilocybin suppresses the default mode network. MDMA reduces amygdala reactivity during trauma processing. Ibogaine resets mu-opioid signaling. Here’s what the science says about the psychology of psychedelic therapy for addiction.
Science & MedicineFrance Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.
France’s ANSM became the first national regulator anywhere to authorize IV racemic ketamine for adult acute suicidal crisis. The US approved esketamine in 2019 but won’t standardize IV ketamine—because it’s a generic with no commercial sponsor.
Science & MedicineThe FDA Just Cleared the First US Ibogaine Trial. It Took 30 Years.
DemeRx received FDA IND clearance for noribogaine—an ibogaine metabolite—for alcohol use disorder. Dr. Deborah Mash has been waiting three decades for this regulatory opening.